Back

Cellectis shares fall 14.6% as Barclays cuts price target to $1.30

Verifying
  • Barclays downgraded Cellectis to Underweight and reduced its price target.
  • Cellectis shares fell 14.6% after the downgrade, while the target dropped to $1.30.
  • Cellectis aims to enter China’s clinic with .HEAL-101 in the first quarter of 2027.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.